Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Details
Publication Year 2025-02,Volume 31,Issue #2,Page 433-441
Journal Title
Nature Medicine
Publication Type
Research article
Abstract
Patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC) have low pathological complete response (pCR) rates with neoadjuvant chemotherapy. A subset of ER+/HER2- BC contains dense lymphocytic infiltration. We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype. We conducted a randomized, multicenter, double-blind phase 3 trial to investigate the benefit of adding nivolumab to neoadjuvant chemotherapy in patients with newly diagnosed, high-risk, grade 3 or 2 (ER 1 to ≤10%) ER+/HER2- primary BC. In total, 510 patients were randomized to receive anthracycline and taxane-based chemotherapy with either intravenous nivolumab or placebo. The primary endpoint of pCR was significantly higher in the nivolumab arm compared with placebo (24.5% versus 13.8%; P = 0.0021), with greater benefit observed in patients with programmed death ligand 1-positive tumors (VENTANA SP142 ≥1%: 44.3% versus 20.2% respectively). There were no new safety signals identified. Of the five deaths that occurred in the nivolumab arm, two were related to study drug toxicity; no deaths occurred in the placebo arm. Adding nivolumab to neoadjuvant chemotherapy significantly increased pCR rates in high-risk, early-stage ER+/HER2- BC, particularly among patients with higher stromal tumor-infiltrating lymphocyte levels or programmed death ligand 1 expression, suggesting a new treatment paradigm that emphasizes the role of immunotherapy and T cell immunosurveillance in luminal disease. Clinical trials.gov identifier: NCT04109066.
Keywords
Humans; Female; *Breast Neoplasms/drug therapy/pathology/genetics; *Nivolumab/administration & dosage/therapeutic use/adverse effects; *Neoadjuvant Therapy; *Receptors, Estrogen/metabolism; Middle Aged; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects; Aged; Adult; Receptor, ErbB-2/metabolism/genetics; Double-Blind Method; Anthracyclines/therapeutic use/administration & dosage; B7-H1 Antigen/antagonists & inhibitors/metabolism
Department(s)
Medical Oncology; Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1038/s41591-024-03414-8
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-01-28 02:47:09
Last Modified: 2025-03-21 02:55:13

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙